Metadon

Methadone, the active ingredient in Metadon, is an opioid agonist presented as a tablet for oral use. It treats opioid dependence and chronic pain in adult patients, helping to suppress withdrawal symptoms and provide long‑term analgesia.

GNH USA supplies Metadon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metadon is an opioid agonist used in the management of conditions related to opioid use and pain control.

- Opioid dependence: suppresses withdrawal symptoms and supports maintenance therapy. - Chronic pain: provides sustained analgesia for long‑term pain management. - Opioid substitution therapy: replaces more harmful opioids with a controlled, longer‑acting agent.

Methadon may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects: - Nausea - Constipation - Drowsiness - Sweating - Dry mouth - Headache

Serious or Rare Side Effects: - Respiratory depression - QT interval prolongation - Severe hypotension - Seizures - Allergic reactions such as rash or angioedema - Adrenal insufficiency

When prescribing Metadon, clinicians should consider several safety measures.

- Cardiac assessment: evaluate QT prolongation risk before initiation. - Respiratory monitoring: observe for signs of respiratory depression, especially during dose adjustments. - Liver function: check hepatic status as metabolism occurs primarily in the liver. - Renal function: adjust dosing in severe renal impairment. - Discontinuation: avoid abrupt cessation to prevent precipitated withdrawal. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Methadone interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines): increased risk of respiratory depression. - Monoamine oxidase inhibitors: risk of serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise methadone plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may reduce methadone concentrations. - Selective serotonin reuptake inhibitors: potential for additive serotonergic effects. - Antihistamines: may enhance sedation and drowsiness.